Guidelines for Authors
www.karger.com/nim_guidelines
 Aims and Scope
Submission
Conditions
Rapid Communications
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Author's ChoiceTM, NIH-Funded Research, Self-Archiving
Proofs
Reprints
Aims and Scope
The rapidly expanding area of research known as neuroimmunomodulation explores the way in which
the nervous system interacts with the immune system via neural, hormonal, and paracrine actions.
Encompassing both basic and clinical research, 'Neuroimmunomodulation' reports on all aspects of
these interactions. Basic investigations consider all neural and humoral interactions from molecular
genetics through cell regulation to integrative systems of the body. The journal also aims to
clarify the basic mechanisms involved in the pathogenesis of the CNS pathology in AIDS patients
and in various neurodegenerative diseases.
Although primarily devoted to research articles, timely reviews will be published on a regular basis.
To ensure high quality, all papers will be reviewed by at least two referees, with every effort made to maintain a short publication time.
Submission
Only original papers written in English are considered and should be submitted online:
Authors are asked to suggest three to four potential reviewers for their manuscript. These experts on the topic of the article should not be from the same institution as the author(s). The names and the full postal and e-mail addresses of potential reviewers should be submitted with each article. Editors will consider these suggestions but are not bound by them.
Should you experience any problems with your submission, please contact
nim@karger.ch
Editorial Office 'Neuroimmunomodulation'
S. Karger AG
Fax +41 61 306 1434
Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Neuroimmunomodulation’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
Most reviews are solicited by the editors. Unsolicited reviews may also be considered, but authors should send a brief proposal to the editorial office, summarizing the topic of the proposed review and 4–5 key references.
Manuscripts should be written in English. They should contain unpublished results of research work, and should be as concise as possible.
The following presentation is recommended: Abstract, Introductory statement on the purpose of the studies, Materials and Methods, Results, Discussion, and References.
Commonly accepted abbreviations (e.g. ACTH, TSH, DNA) may be used throughout the text and tables, but a definition should be provided the first time each abbreviation is used. Please limit abbreviations to those in common use, and avoid other abbreviations and acronyms.
Contributions will generally be printed in order of acceptance for publication.
All studies based on experiments/trials conducted with humans or animals must have been approved by the author's institutional review board. This board's ethical approval must be declared within the methods section. All patients referred to in human studies should be identified by numbers or aliases, not by their real names, and must have provided informed consent prior to their inclusion in the study. All clinical investigations must have been conducted according to Declaration of Helsinki principles. Manuscripts failing to comply with these requirements will not be considered for publication.
Papers that do not meet these criteria will not be accepted for publication.
Rapid Communications
Manuscripts intended for rapid communication must present new findings of sufficient importance to justify their accelerated appearance. Double-spaced manuscripts cannot exceed 7 pages, including figures, tables and references; longer manuscripts will be returned. Rapid communications are subject to the usual editorial review and are published within 2 months following acceptance. Proofs are sent to the Editors and to the authors.
Arrangement
Title page: The first page of each paper should carry the title, the authors’ full first and last names, and the name of the institute or department where the authors conducted their research work.
In addition, the following should be put on the title page:
1. A short title for use as a running head;
2. A list of 3–9 key words for indexing purposes;
3. The name and complete mailing address as well as phone and fax numbers as well as e-mail address of the individual to whom correspondence, proofs, and requests for reprints should be addressed.
Abstract: Each paper needs an abstract of up to 250 words.
Abstracts for Original Papers should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).
The words used in the subheadings of the Abstract are not included in the 250 words of the Abstract.
Footnotes: Avoid footnotes if at all possible. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.
Acknowledgments, including, where relevant, credit to the sources of grant support, should be placed before the references.
Tables and illustrations: Tables (numbered in arabic numerals) should be prepared on separate sheets, and each should have a suitable heading. Illustrations should be numbered in Arabic numerals and legends for the figures should be submitted on a separate page. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 181 x 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author’s name, and ‘top’ with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1200 dpi.
Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 760.000 per page.
References
In the text identify references by Arabic numerals [in square brackets]. Papers that have been submitted to a journal but are not yet accepted should not be listed in the bibliography, but the data in them can be referred to in the text as unpublished observations. If details of methods are only available in papers that are ‘in press’, copies of the papers should be included with the manuscript submitted to ‘Neuroimmunomodulation’, so that the editorial referees can have adequate information to judge the manuscript. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of all the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. (Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309–315. www.icmje.org)
|
(a) Papers published in periodicals: Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. Int Arch Allergy Immunol 1997;112:191–195.
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
(c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.
(d) Edited books: Parren PWHI, Burton DR: Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy; in Capra JD (ed): Antibody Engineering. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18–56.
(e) Papers published in electronic format: Black CA: Delayed type hypersensitivity.
Current theories with a historic perspective. Dermatol Online J 1999;5:7.
http://dermatology.cdlib.org/DOJvol5num1.
|
Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org
Author's ChoiceTM
Karger's Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 2,750.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available here.
Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.
Proofs
Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author. No page proofs are supplied.
Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
|
|
|
| Search in this journal
|
|
|
|
For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|
Online Manuscript Submission
Guidelines
